On the stock market since 2007, it operates in the world of health and science. It has 1 employee. Now — the numbers.
This is an established company with proven profits.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $636K. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 18 buys and 6 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.0014. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, IMTH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMTH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.